Preclinical and clinical studies suggest the potential role of DPP4-i, of GLP-1 receptor agonist and, most recently, of GLP-1/GIP dual receptor agonists as therapy for the treatment and prevention of cognitive impairment and dementia. The gene discussed is GLP1R; the disease is dementia.